Core Viewpoint - Yabao Pharmaceutical reported a decline in both revenue and net profit for the first three quarters of 2025, indicating a downturn in performance compared to previous years [1][2]. Financial Performance - For the first three quarters of 2025, Yabao Pharmaceutical achieved revenue of 1.709 billion yuan, a year-on-year decrease of 19.46% [1]. - The net profit attributable to shareholders was 215 million yuan, down 8.44% year-on-year [1]. - The third quarter revenue was 569 million yuan, reflecting a 16.01% decline compared to the same period last year [1]. - The net profit for the third quarter was approximately 40.7 million yuan, a significant drop of 26.22% year-on-year [1]. Product Performance - Sales of the flagship product, Dinggui Er Qi贴, decreased by 10.60% to 85.83 million patches, equating to a loss of approximately 10.18 million patches compared to 2023 [2]. - The decline in revenue for the first half of the year was attributed to reduced income from various products, including 消肿止痛贴 and 盐酸倍他司汀注射液 [2]. R&D Developments - The significant drop in total profit for the third quarter was primarily due to the termination of the SY-009 research and development project, which led to asset impairment provisions [2]. - SY-009, a sodium-glucose co-transporter 1 inhibitor intended for type 2 diabetes treatment, did not meet its primary efficacy endpoint in phase II clinical trials, leading to uncertainty in further development [3]. - As of the announcement date, the investment in SY-009's R&D had reached approximately 87.87 million yuan [3].

Core Viewpoint - The company reported a significant decline in revenue and net profit for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The company achieved a revenue of 1.709 billion yuan, representing a year-on-year decrease of 19.46% [1] - The net profit attributable to shareholders was 215 million yuan, down 8.44% year-on-year [1] - The non-recurring net profit was 197 million yuan, reflecting a decline of 9.03% compared to the previous year [1] - The basic earnings per share stood at 0.3066 yuan [1]

亚宝药业集团股份有限公司 董事及高级管理人员离职管理制度 第一章 总则 第一条 为规范亚宝药业集团股份有限公司（以下简称"公司"）董事及高 级管理人员离职管理事宜，保障公司治理结构的连续性和稳定性，维护公司及全 体股东的合法权益，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《上市公司章程指引》《上市公司治理准则》及《亚宝药业集团股份有限公司章 程》（以下简称"公司章程")的规定，制定本制度。 第二条 本制度适用于公司董事（含独立董事）及高级管理人员因任期届满 未连任、辞任、解任及其他导致董事及高级管理人员实际离职等情形。 第二章 离职情形与生效条件 第三条 董事任期3年，任期届满可以连选连任，但独立董事连任时间不得超 过六年。董事任期届满未获连任的，自换届的股东会决议通过之日自动离职。股 东会可以决议解任董事，决议作出之日解任生效。无正当理由，在任期届满前解 任董事的，董事可以要求公司予以赔偿。 第四条 如存在以下情形的，在改选出的董事就任前，原董事仍应当依照法 律、行政法规、部门规章和公司章程规定，履行董事职务，但存在相关法规另有 规定的除外： （一）董事任期届满未及时改选，或者董事在任期内辞 ...

亚宝药业集团股份有限公司 信息披露制度 第一章 总则 第一条 为规范亚宝药业集团股份有限公司（以下简称"公司"）信息披露行为， 加强信息披露事务管理，维护公司和投资者的合法权益，根据《中华人民共和国公司 法》（以下简称"《公司法》"）《中华人民共和国证券法》（以下简称"《证券法》"）《上 市公司信息披露管理办法》《上海证券交易所股票上市规则》（以下简称"《股票上市 规则》"）以及《亚宝药业集团股份有限公司章程》（以下简称"公司章程"）的有关规 定，并结合公司的实际情况，制定本制度。 第二条 本制度所称"信息"是指所有可能对公司股票及其衍生品种交易价格产生 重大影响的信息，以及证券监督管理部门和上海证券交易所要求或公司主动披露的信 息；本制度所称"披露"是指在规定的时间内，在中国证券监督管理委员会（以下简 称"中国证监会"）指定的媒体上，以规定的方式向社会公众公布前述信息，并按规 定报送证券监管部门和上海证券交易所。 第三条 公司的信息披露义务人包括但不限于： （一）公司及全体董事、高级管理人员； （二）公司股东、实际控制人； （三）收购人及其他权益变动主体，重大资产重组、再融资、重大交易有关各方 等自然人、单 ...

亚宝药业集团股份有限公司 董事和高级管理人员所持本公司股份及其变动管理制度 第一章 总则 第一条 为加强对亚宝药业集团股份有限公司（以下简称"公司"）董事和 高级管理人员所持本公司股份及其变动的管理，根据《中华人民共和国公司法》 （以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券 法》"）、《上市公司董事和高级管理人员所持本公司股份及其变动管理规则》 《上市公司股东减持股份管理暂行办法》《上海证券交易所股票上市规则》（以 下简称"《股票上市规则》"）《上海证券交易所上市公司自律监管指引第8 号——股份变动管理》《上海证券交易所上市公司自律监管指引第15号——股东 及董事、高级管理人员减持股份》等法律、行政法规、部门规章、规范性文件 （以下统称"法律法规"），以及《亚宝药业集团股份有限公司章程》（以下简 称"公司章程"）的有关规定，制定本制度。 公司董事、高级管理人员等主体对持有股份比例、持有期限、变动方式、 变动数量、变动价格等作出承诺的，应当严格履行所作出的承诺。 第三条 公司董事和高级管理人员所持本公司股份，是指登记在其名下和利 用他人账户持有的所有本公司股份。 公司董事和高级管理人员 ...

证券代码：600351 证券简称：亚宝药业 公告编号：2025-039 亚宝药业集团股份有限公司 第九届董事会第十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 亚宝药业集团股份有限公司（以下简称"公司"）第九届董事会第十次会议通 知于 2025 年 10 月 14 日以电子邮件和电话的方式发出，会议于 2025 年 10 月 24 日在公司北京企管中心会议室召开,会议应到董事 9 人，实到董事 9 人，符合《公 司法》及《公司章程》的有关规定。公司高级管理人员列席了会议。会议由公司 董事长任武贤先生主持，会议审议并经表决通过了如下决议： 一、审议通过了公司 2025 年第三季度报告； 同意 9 票，反对 0 票，弃权 0 票。 具体内容详见上海证券交易所网站（www.sse.com.cn）。 三、审议通过了关于制定《亚宝药业集团股份有限公司董事和高级管理人员 所持本公司股份及其变动管理制度》的议案； 同意 9 票，反对 0 票，弃权 0 票。 具体内容详见上海证券交易所网站（www.sse.com.cn）。 ...

Core Viewpoint - The financial performance of Yabao Pharmaceutical (600351) has declined significantly in Q3 2025, primarily due to the termination of the SY009 research project and the provision for asset impairment [1] Financial Performance Summary - Q3 2025 revenue reached 569 million yuan, a year-on-year decrease of 16.01% [1] - Q3 2025 net profit was 40.6971 million yuan, down 26.22% year-on-year [1] - Revenue for the first three quarters totaled 1.709 billion yuan, reflecting a 19.46% year-on-year decline [1] - Net profit for the first three quarters was 215 million yuan, a decrease of 8.44% year-on-year [1] - Basic earnings per share stood at 0.3066 yuan [1]

Financial Performance - The company's operating revenue for Q3 2025 was ¥569,303,758.32, a decrease of 16.01% compared to the same period last year[2] - Total profit for the quarter was ¥40,933,824.50, down 42.51% year-on-year[2] - Net profit attributable to shareholders was ¥40,697,053.18, reflecting a decline of 26.22% compared to the previous year[2] - The company reported a decrease of 30.84% in net profit after deducting non-recurring gains and losses due to the termination of the SY009 R&D project[7] - The basic earnings per share for the quarter was ¥0.0583, down 24.23% year-on-year[2] - Total revenue for the first three quarters of 2025 was CNY 1,708,712,223.13, a decrease of 19.4% compared to CNY 2,121,509,818.79 in the same period of 2024[16] - Net profit for the first three quarters of 2025 was CNY 198,491,469.17, down 13.1% from CNY 228,467,854.51 in the same period of 2024[18] - Earnings per share for the first three quarters of 2025 was CNY 0.3066, compared to CNY 0.3241 in 2024, reflecting a decrease of 5.5%[18] Cash Flow and Assets - The net cash flow from operating activities increased significantly by 221.16% to ¥129,363,179.19[2] - Cash and cash equivalents increased to ¥645,407,882.65 from ¥578,594,453.98, reflecting a growth of approximately 11.43%[13] - Total current assets decreased to ¥1,484,605,647.29 from ¥1,559,311,767.72, a decline of about 4.79%[13] - Cash inflow from sales of goods and services was $1.64 billion, compared to $1.84 billion in the previous period, reflecting a decrease of 11.1%[21] - Total cash outflow from operating activities was $1.30 billion, down from $1.52 billion in the previous period, indicating a reduction of 14.4%[21] - Cash received from investment recoveries was $144.77 million, a significant increase from $4.87 million in the previous period[22] - Cash paid for fixed assets and intangible assets was $38.77 million, compared to $28.32 million in the previous period, representing an increase of 36.8%[22] Shareholder Information - Total shareholders at the end of the reporting period reached 53,669[9] - The largest shareholder, Shanxi Yabao Investment Group Co., Ltd., holds 94,300,000 shares, accounting for 13.47% of total shares[9] - The top ten shareholders do not have any related party relationships or concerted actions among them[11] - The company has not reported any significant changes in the participation of major shareholders in securities lending or borrowing activities[11] Assets and Liabilities - The total assets at the end of the reporting period were ¥3,342,721,351.58, a decrease of 5.68% from the end of the previous year[3] - The equity attributable to shareholders decreased by 3.35% to ¥2,795,760,982.69[3] - Total liabilities decreased to CNY 585,773,356.92 from CNY 649,023,044.55, a reduction of 9.8%[15] - Non-current assets totaled CNY 1,858,115,704.29, down from CNY 1,984,630,806.62, indicating a decrease of 6.4%[15] Operating Costs and Expenses - Total operating costs for the first three quarters of 2025 were CNY 1,422,105,604.68, down from CNY 1,854,942,934.53 in 2024, reflecting a reduction of 23.3%[16] - Operating profit for the first three quarters of 2025 was CNY 253,258,850.67, compared to CNY 288,373,771.98 in 2024, indicating a decline of 12.2%[17] - The company reported a significant reduction in sales expenses, which were CNY 327,463,027.22 in 2025 compared to CNY 514,819,616.99 in 2024, a decrease of 36.3%[17] - Research and development expenses for the first three quarters of 2025 were CNY 72,291,467.66, down from CNY 89,911,769.62 in 2024, reflecting a decrease of 19.7%[17]

格隆汇10月24日丨亚宝药业(600351.SH)公布三季度报告，前三季营业收入17亿元，同比下降19.46%， 归属于上市公司股东的净利润2.15亿元，同比下降8.44%，归属于上市公司股东的扣除非经常性损益的 净利润1.97亿元，同比下降9.03%。 ...

Core Insights - The company reported a third-quarter revenue of 569 million yuan, representing a year-on-year decline of 16.01% [1] - The net profit for the third quarter was 40.7 million yuan, down 26.22% year-on-year [1] - For the first three quarters, the total revenue was 1.709 billion yuan, reflecting a year-on-year decrease of 19.46% [1] - The net profit for the first three quarters amounted to 215 million yuan, which is an 8.44% decline compared to the previous year [1]